RESOURCES FOR YOU

 

Pocket Guide Image

POCKET GUIDE
 

Key facts about
SHINGRIX

 

 

View

Administration Reference Guide Image

ADMINISTRATION REFERENCE GUIDE

Storage, reconstitution,
and administration of
SHINGRIX

 

 

View

CDC Recommendation Guide Image

2018 CDC RECOMMENDATIONS SUMMARY

Summary of recommendations by the Advisory Committee on Immunization Practices (adopted by the CDC)

 

View

Chat Icon Learn more about SHINGRIX by attending a webinar. Sign up today!

RESOURCES FOR YOUR PATIENTS

What To Expect Guide Image

WHAT TO EXPECT
 

Everything your patients should know when receiving SHINGRIX

View

Second Dose Reminder Card Image

SECOND DOSE
REMINDER CARD

Provide your patients a reminder card for their follow-up visit

View


Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%)
  • Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%)
  • SHINGRIX was not studied in pregnant or lactating women, and it is unknown if it is excreted in human milk. Therefore, it cannot be established whether there is vaccine-associated risk with SHINGRIX in pregnant women or if there are effects on breastfed infants or milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

All trademarks are the property of their respective owners.

826948R0 February 2018